A5014614254- Long-Term Effects of COVID-19
- Pharmacological Receptor Mechanisms and Effects
- COVID-19 Clinical Research Studies
- Schizophrenia research and treatment
- COVID-19 and Mental Health
- Sphingolipid Metabolism and Signaling
- Tryptophan and brain disorders
- Bipolar Disorder and Treatment
- COVID-19 epidemiological studies
- Workplace Health and Well-being
- SARS-CoV-2 and COVID-19 Research
- Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Employment and Welfare Studies
- Intensive Care Unit Cognitive Disorders
- COVID-19 Pandemic Impacts
- Health disparities and outcomes
- Family Caregiving in Mental Illness
- Mental Health Treatment and Access
- Retirement, Disability, and Employment
- Substance Abuse Treatment and Outcomes
- Mental Health Research Topics
- COVID-19 and healthcare impacts
- Sleep and Wakefulness Research
- Vaccine Coverage and Hesitancy
- Sleep and related disorders
Hôpital Corentin-Celton
2020-2025
Université Paris Cité
2020-2025
Assistance Publique – Hôpitaux de Paris
2020-2025
Universidad Complutense de Madrid
2019-2024
Sorbonne Paris Cité
2024
Inserm
2021-2022
Institut de Psychiatrie et Neurosciences de Paris
2021-2022
Université Sorbonne Paris Nord
2020-2022
Universidad Francisco de Vitoria
2022
University of Minnesota Medical Center
2022
Many European countries have responded to the COVID-19 pandemic by implementing nationwide protection measures and lockdowns1. However, epidemic could rebound when such are relaxed, possibly leading a requirement for second or more, repeated lockdowns2. Here, we present results of stochastic agent-based microsimulation model in France. We examined potential impact post-lockdown measures, including physical distancing, mask-wearing shielding individuals who most vulnerable severe infection,...
Several medications commonly used for a number of medical conditions share property functional inhibition acid sphingomyelinase (ASM), or FIASMA. Preclinical and clinical evidence suggest that the ASM/ceramide system may be central to severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2) infection. We examined potential usefulness FIASMA use among patients hospitalized coronavirus disease 2019 (COVID‐19) in an observational multicenter study conducted at Greater Paris University...
Haloperidol, a widely used antipsychotic, has been suggested as potentially useful for patients with COVID-19 on the grounds of its in-vitro antiviral effects against SARS-CoV-2, possibly through sigma-1 receptor antagonist effect.We examined associations haloperidol use intubation or death and time to discharge home among adult hospitalized at Assistance Publique-Hôpitaux de Paris (AP-HP) Greater University hospitals. Study baseline was defined date hospital admission. The primary endpoint...
Abstract The acid sphingomyelinase (ASM)/ceramide system may provide a useful framework for better understanding SARS-CoV-2 infection and the repurposing of psychotropic medications functionally inhibiting sphingomyelinase/ceramide (named FIASMA medications) against COVID-19. We examined potential usefulness in patients with psychiatric disorders hospitalized severe COVID-19, an observational multicenter study conducted at Greater Paris University hospitals. Of 545 adult inpatients, 164...
To examine the association between dexamethasone use and mortality among patients hospitalized for COVID-19.We examined at AP-HP Greater Paris University hospitals. Study baseline was defined as date of hospital admission. The primary endpoint time to death. We compared this who received those did not in time-to-event analyses adjusted patient characteristics (such age, sex comorbidity) clinical biological markers severity COVID-19, stratified by need respiratory support, i.e. mechanical...
This cohort study examines the prevalence of contraindications to nirmatrelvir-ritonavir in patients hospitalized with COVID-19.
In this multicenter retrospective observational study involving 58 562 adult patients hospitalized for COVID-19, melatonin use (N = 272) at a mean daily dose of 2.6 mg was not associated with reduced mortality.
To reduce Coronavirus Disease 2019 (COVID-19)-related mortality and morbidity, widely available oral COVID-19 treatments are urgently needed. Certain antidepressants, such as fluvoxamine or fluoxetine, may be beneficial against COVID-19. We included 388,945 adult inpatients who tested positive for SARS-CoV-2 at 36 AP−HP (Assistance Publique−Hôpitaux de Paris) hospitals from 2 May 2020 to November 2021. compared the prevalence of antidepressant use admission in a 1:1 ratio matched analytic...
The coronavirus disease 2019 (COVID-19) pandemic continues to cause significant morbidity and mortality worldwide. Since a large portion of the world's population is currently unvaccinated or incompletely vaccinated has limited access approved treatments against COVID-19, there an urgent need continue research on treatment options, especially those at low cost which are immediately available patients, particularly in low- middle-income countries. Prior vitro observational studies have shown...
Uncertainty exists over whether atypical and typical antipsychotics differ in the strength of their association with mortality among older people schizophrenia. Here, we examined rates its causes significantly between adults schizophrenia taking or antipsychotics. In a 5-year prospective multicenter study patients aged ≥55 years an ICD-10 diagnosis schizophrenia, used multivariable logistic regression model to examine versus mortality, adjusting for sociodemographic clinical characteristics....
ABSTRACT Objective To examine the association between antidepressant use and risk of intubation or death in hospitalized patients with COVID-19. Design Multicenter observational retrospective cohort study. Setting Greater Paris University hospitals, France. Participants 7,345 adults COVID-19 24 January 1 April 2020, including 460 (6.3%) who received an during visit. Data source Assistance Publique-Hôpitaux de Health Warehouse. Main outcome measures The primary endpoint was a composite death....
Prior research suggests that psychiatric disorders could be linked to increased mortality among patients with COVID-19. However, whether all or specific are intrinsic risk factors of death in COVID-19 these associations reflect the greater prevalence medical people has yet evaluated.We performed an observational, multicenter, retrospective cohort study examine association between and hospitalized for laboratory-confirmed at 36 Greater Paris University hospitals.Of 15,168 adult patients, 857...
Abstract Prior research suggests that fluvoxamine, a selective serotonin reuptake inhibitor (SSRI) used for the treatment of obsessive-compulsive disorder and major depressive disorder, could be repurposed against COVID-19. We undertook prospective interventional open-label cohort study to evaluate efficacy tolerability fluvoxamine among inpatients with laboratory-confirmed COVID-19 in Uganda. The main outcome was all-cause mortality. Secondary outcomes were hospital discharge complete...
Prior evidence indicates the potential central role of acid sphingomyelinase (ASM)/ceramide system in infection cells with SARS-CoV-2. We conducted a multicenter retrospective observational study including 72,105 adult patients laboratory-confirmed SARS-CoV-2 who were admitted to 36 AP-HP (Assistance Publique-Hôpitaux de Paris) hospitals from 2 May 2020 31 August 2022. examined association between ongoing use medications functionally inhibiting (FIASMA), which reduces vitro, upon hospital...
Abstract Most European countries have responded to the COVID-19 threat by nationwide implementation of barrier measures and lockdown. However, assuming that population immunity will build up through epidemic, it is likely rebound once these are relaxed, possibly leading a second or multiple repeated lockdowns. In this report, we present results epidemiological modelling has helped inform policy making in France. We used stochastic agent-based microsimulation model epidemic France, examined...
(1) Background: Based on its antiviral activity, anti-inflammatory properties, and functional inhibition effects the acid sphingomyelinase/ceramide system (FIASMA), we sought to examine potential usefulness of H1 antihistamine hydroxyzine in patients hospitalized for COVID-19. (2) Methods: In a multicenter observational study, included 15,103 adults COVID-19, which 164 (1.1%) received within first 48 h hospitalization, administered orally at median daily dose 25.0 mg (SD = 29.5). We compared...
Objective: Sleep alterations have been suggested as a cause and consequence of psychiatric disorders. In this context, we evaluated the incidence disorders following sleep complaints in adults with major depressive episode (MDE).Methods: large, nationally representative 3-year prospective survey, National Epidemiologic Survey on Alcohol Related Conditions conducted 2001-2002 (Wave 1) 2004-2005 2), used structural equation modeling to examine shared specific effects trouble falling asleep,...
To examine the association between benzodiazepine receptor agonist (BZRA) use and mortality in patients hospitalised for coronavirus disease 2019 (COVID-19).A multicentre observational study was performed at Greater Paris University hospitals. The sample involved 14 381 COVID-19. A total of 686 (4.8%) inpatients received a BZRA hospital admission mean daily diazepam-equivalent dose 19.7 mg (standard deviation (s.d.) = 25.4). baseline date admission, primary endpoint death. We compared this...
The study of diagnostic associations entails a large number methodological problems regarding the application machine learning algorithms, collinearity and wide variability being some most prominent ones. To overcome these, we propose tested usage uniform manifold approximation projection (UMAP), very recent, popular dimensionality reduction technique. We showed its effectiveness by using it on Spanish clinical database patients diagnosed with depression, to whom applied UMAP before grouping...